<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, May 9, 2018 (HealthDay News) — The correlation between the apolipoprotein E (APOE<\/i>) gene allele APOE<\/i>-\u03b54 and cerebrospinal fluid (CSF) tau levels is stronger among women than men, according to a study published online May 7 in JAMA Neurology<\/i>.<\/p>\n
Timothy J. Hohman, Ph.D., from Vanderbilt University Medical Center in Nashville, Tenn., and colleagues examined sex differences in the correlation between APOE<\/i> and markers of Alzheimer’s disease (AD) neuropathology measured in CSF in a multicohort study using data from 10 longitudinal cohort studies. Data were included for 1,798 patients in a CSF biomarker cohort, of whom 862 were women and 226 had AD. A total of 5,109 patients were included in the autopsy cohort, of whom 2,813 were women.<\/p>\n
The researchers observed a significant interaction between APOE<\/i>-\u03b54 and sex on CSF total tau and phosphorylated tau, with a stronger correlation for APOE<\/i> among women than men. In post-hoc analyses, this sex difference was seen in amyloid-positive, but not amyloid-negative, individuals. Sex differences were not seen in the correlation between APOE<\/i> and \u03b2-amyloid 42, neuritis plaque burden, or neurofibrillary tangle burden.<\/p>\n
“Together, the sex difference in the association between APOE<\/i> and CSF measures of tau and the lack of a sex difference in the association with neurofibrillary tangles at autopsy suggest that APOE<\/i> may modulate risk for neurodegeneration in a sex-specific manner, particularly in the presence of amyloidosis,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry. The Alzheimer’s Disease Neuroimaging Initiative partially funded the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n